The following video is from Thursday's Investor Beat, in which host Rex Moore, and analysts Jason Moser and Matt Koppenheffer dissect the hardest-hitting investing stories of the day.
The market saw continued volatility today as those crazy traders are still worried about the Fed's signals that it might ease back on its bond-buying program that's helped the recovery.
In this installment of Investor Beat, Motley Fool analysts Jason Moser and Matt Koppenheffer question whether investors should really be worrying, and which stocks look attractive for the long term.
Now more than ever, it's essential to take control of your investments if you want to have a financially secure retirement. The Fool wants to help you retire rich, so we've put together a research report with three promising stocks specifically chosen with long-term retirement investors in mind. Don't miss out on this absolutely free report; click here and get your copy today!�
10 Best Heal Care Stocks To Own For 2015: ICL Israel Chemicals Ltd (ICL)
ICL Israel Chemicals Ltd (ICL) is an Israel-based company, engaged in the fertilizer and specialty chemical sectors. The company operates in three segments: Fertilizers, Industrial Products, and Performance Products. The Fertilizers segment is engaged in the production of standard, granular, fine red and white potash from three sources, as well as in the production of phosphates, such as phosphate rock, phosphoric acid, fertilizers and animal feed addictives. The Industrial Products segment produces flame retardants, such as brominates and organ phosphorus; elemental bromine, and other chemicals. In addition the Performance Products segment produces specialty phosphates, such as technical, food grade and electronic grade phosphoric acid, phosphate salts, food additives and wildfire safety products, as well as alumina and other chemicals. Advisors' Opinion:- [By Claudia Maedler]
In Israel, the TA-25 Index (TA-25) gained 1.9 percent at the close in Tel Aviv as Israel Corp. jumped 9 percent, the most since July 2009, to 1,755 shekels. The shares soared along with those of its Israel Chemicals Ltd. (ICL) unit, which advanced 6.4 percent on speculation that a possible change in ownership of Russian potash producer OAO Uralkali could help stabilize prices of the crop nutrient.
- [By Gwen Ackerman]
Israel Chemicals Ltd. (ICL), the fourth-largest potash producer in the world by sales, is weighing on the Tel Aviv benchmark stock index on concern the government will exact higher royalties amid a global oversupply.
Top Heal Care Companies For 2014: MEDNAX Inc (MD)
MEDNAX, Inc. (MEDNAX), incorporated in 2007, is a provider of physician services, including newborn, maternal-fetal, pediatric subspecialties and anesthesia care. As of December 31, 2011, the Company�� national network consisted of 1,839 affiliated physicians, including 996 physicians who provided neonatal clinical care, in 34 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company has 190 affiliated physicians who provide maternal-fetal care to expectant mothers experiencing complicated pregnancies and obstetrical hospitalist services in many areas where its affiliated neonatal physicians practice. In March 2014, the Company acquired Piedmont Neonatology, P.C.Piedmont Neonatology, P.C, is a private neonatal physician group practice based in Greensboro, North Carolina.
MEDNAX�� network includes other pediatric subspecialists, including 108 physicians providing pediatric cardiology care, 85 physicians providing pediatric intensive care, 43 physicians providing hospital-based pediatric care and six physicians providing pediatric surgical care. In addition, it has 411 physicians who provide anesthesia care to patients in connection with surgical and other procedures, as well as pain management. The Company provides clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through a team of neonatal physician subspecialists (neonatologists), neonatal nurse practitioners and other pediatric clinicians. Neonatal nurse practitioners are nurses who have training and education in managing the healthcare needs of newborns, infants and their families.
MEDNAX provides outpatient and inpatient clinical care to expectant mothers and their unborn babies through its affiliated maternal-fetal medicine subspecialists, obstetricians and other clinicians, such as maternal-fetal nurse practitioners, nurse mid-wives, ultrasonogra! phers and genetic counselors. It provides inpatient and outpatient pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through its affiliated pediatric cardiologist subspecialists and other clinicians, such as pediatric nurse practitioners, echocardiographers and other diagnostic technicians, and exercise physiologists.
The Company�� network includes pediatric intensivists, who are hospital-based pediatricians with education and training in caring for critically ill or injured children and adolescents, pediatric hospitalists, who are hospital-based pediatricians specializing in inpatient care and management of acutely ill children and pediatric surgeons, who provide specialized care for patients ranging from newborns to adolescents, for all problems or conditions affecting children that require surgical intervention. Its affiliated physicians also provide clinical services in other areas of hospitals, particularly in the labor and delivery area and nursery and pediatric department.
The Company provides anesthesia care through a team of physician anesthesiologists, certified registered nurse anesthetists (CRNAs) and anesthesia assistants (AAs). The Company also provides acute and chronic pain management services. Postoperative acute pain management is often initiated in the hospital recovery room and may continue for the remainder of the hospital stay. Chronic pain services are offered through outpatient medical offices or hospital clinics.
Advisors' Opinion:- [By Seth Jayson]
MEDNAX (NYSE: MD ) is expected to report Q2 earnings around July 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MEDNAX's revenues will increase 18.4% and EPS will grow 11.5%. - [By Bryan Murphy]
Looking for some fresh trading ideas in a market environment that isn't offering many? Take a look at MEDNAX Inc. (NYSE:MD) and Westport Innovations Inc. (NASDAQ:WPRT). Though they're pointed in different directions, both MD and WPRT appear to be on the verge of trade-worthy moves. The fact that the two are nearly mirror images of one another is strictly coincidental.
Top Heal Care Companies For 2014: Guided Therapeutics Inc (GTHP)
Guided Therapeutics, Inc., incorporated on October 27, 1992, is a medical technology company focused on developing medical devices. The Company�� primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.
The Company's product, in addition to detecting the structural changes attributed to cervical cancer, is also designed to detect the biochemical changes that precede the development of visual lesions. The product is expected to incorporate a single-use, disposable calibration and alignment component.
The Company competes with Qiagen, MediSpectra, Inc., Merck & Co., Inc., and GlaxoSmithKline PLC.
Advisors' Opinion:- [By CRWE]
Today, GTHP remains (0.00%) +0.000 at $.710 with 44,700 shares in play thus far (ref. google finance Delayed: 11:42AM EDT August 21, 2013).
Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.
Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.
- [By CRWE]
Last Friday, GTHP had shed (-2.16%) down -0.015 at $.679 with 39,538 shares in play at the close (ref. google finance August 23, 2013 ��Close).
Guided Therapeutics, Inc. previously reported its operating results for the second quarter and six months ended June 30, 2013.
Revenue and other income for the second quarter of 2013 was approximately $338,000, including $116,000 in sales of LuViva庐 devices and disposables associated with its European launch, with the remainder of revenue representing contract and grant income. This compares to revenue of approximately $944,000 in the second quarter of 2012, which was comprised almost solely of contract and grant income. Revenue for the first six months of 2013 was $637,000, including $248,000 in sales of LuViva device and disposables. Revenue in the first six months of 2012 was $1.6 million, which was comprised almost solely of contract and grant income. The year over year decline in contract and grant income for both periods was primarily due to bringing the worldwide rights to the Company�� esophageal cancer detection technology back in house.
Top Heal Care Companies For 2014: Pervasive Software Inc.(PVSW)
Pervasive Software, Inc. provides embeddable software and SaaS services for data management, data integration, B2B exchange, and analytics. Its embeddable Pervasive PSQL database engine provides database reliability in a near-zero database administration environment for packaged business applications. Pervasive Software?s multi-purpose data integration platform, available on-premises and in the cloud, accelerates the sharing of information between multiple data stores, applications, and hosted business systems, and allows customers to re-use the same software for diverse integration scenarios. Pervasive DataRush is an embeddable parallel-processing platform enabling data-intensive applications, such as claims processing, risk analysis, fraud detection, data mining, predictive analytics, sales optimization, and marketing analytics. The company serves customers in approximately 150 countries. Pervasive Software, through Pervasive Innovation Labs, also invests in the explorat ion and creation of solutions for the data analysis and data delivery challenges. Pervasive Software, Inc. has a strategic alliance with A.D.A.M. Inc. The company was founded in 1994 and is headquartered in Austin, Texas with additional offices in Greenville, South Carolina; Brussels, Belgium; Frankfurt, Germany; Paris, France; and London, the United Kingdom.
Advisors' Opinion:- [By CRWE]
Pervasive Software(R) Inc. (NASDAQ:PVSW), a global leader in cloud-based and on-premises data innovation, reported that it is in receipt of an unsolicited non-binding letter from Actian Corporation proposing to acquire all of the outstanding shares of Pervasive common stock for $8.50 per share in cash.
Top Heal Care Companies For 2014: LSI Industries Inc.(LYTS)
LSI Industries Inc. provides corporate visual image solutions primarily in the United States, Canada, Australia, and Latin America. It operates in three segments: Lighting, Graphics, and Technology. The Lighting segment manufactures and markets outdoor and indoor lighting, canopy lighting, landscape lighting, light emitting diodes (LED) lighting, light poles, and photometric layouts products, as well as lighting analysis services. The Graphics segment manufactures and sells exterior and interior visual image elements for use in visual image programs. It offers signage and canopy graphics; pump dispenser graphics; building fascia graphics; decals; interior signage and marketing graphics; aisle markers; wall mural graphics; fleet graphics; prototype program graphics; and solid state LED video screens for the sports and advertising markets, as well as installation services for graphics products. The Technology segment designs, produces, and supports light engines and large fo rmat video screens using LED technology; and specialty LED lighting. Additionally, the company offers menu board systems. It serves commercial, industrial, and multi-site retail markets; petroleum/convenience stores; sports and advertising; and entertainment markets. The company sells its products through regional sales managers, independent sales representatives, and distributors. LSI Industries was founded in 1976 and is headquartered in Cincinnati, Ohio.
Advisors' Opinion:- [By Dan Caplinger]
In Daktronics' report, be sure to look at how the company compares to results that industrial-lighting and display competitor LSI Industries (NASDAQ: LYTS ) announced late last month. Even with a 5% gain in revenue for its March quarter, LSI posted a loss, showing the difficulty in producing high-margin business in the industry. For its part, if Daktronics can keep pushing past its operational challenges, it should be in better position to stay profitable both this quarter and well into the future.
Top Heal Care Companies For 2014: Hanger Orthopedic Group Inc.(HGR)
Hanger Orthopedic Group, Inc. engages in the ownership and operation of orthotic and prosthetic (O&P) patient care centers in the United States. The company provides orthotic and prosthetic patient care services. Its orthotics business include the design, fabrication, fitting, and maintenance of a range of standard and custom-made braces and other devices that provide external support to patients suffering from musculoskeletal disorders, such as ailments of the back, extremities or joints, and injuries from sports or other activities. The company?s prosthetics business comprise designing, fabricating, fitting, and maintaining custom-made artificial limbs for patients, who are without limbs as a result of traumatic injuries, vascular diseases, diabetes, cancer, or congenital disorders. It also distributes branded and private label O&P devices, as well as develops programs to manage various aspects of O&P patient care for insurance companies. In addition, the company manufac tures and distributes therapeutic footwear for diabetic patients in the podiatric market, as well as develops and provides specialized rehabilitation technologies and integrated clinical programs to rehabilitation providers. As of June 30, 2011, it operated approximately 675 patient-care centers in 45 states and the District of Columbia. The company, formerly known as Sequel Corporation, was founded in 1861 and is headquartered in Austin, Texas.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Alamy There are plenty of stocks going up -- and down -- in any given week. The gainers inspire us to keep investing. The decliners keep greed in check while reminding us about the risks of the equity markets. Let's go over some of last week's best and worst performers. Pike (PIKE) -- Up 49 percent last week The market's biggest winner of last week was Pike, a specialty construction and engineering firm that received a bid to be taken private. J. Eric Pike -- the firm's chairman and CEO -- is teaming up with private equity firm Court Square Capital Partners to buy out shareholders at $12 a share. It's a fair premium, pricing the buyout at a better than 50 percent premium to where the stock was trading when it was announced. A few attorneys are trying to smoke out investors who feel that the CEO-led privatization push isn't fair, but it's likely to stick at that kind of healthy markup. Pike shares may have traded in the low teens last summer, but that was before revenue and earnings began heading the wrong way. Most shareholders should be more than happy to take the money and run. RadNet (RDNT) -- Up 34 percent last week Operating a network of 251 facilities that perform outpatient diagnostic imaging services is looking good for RadNet. The stock moved sharply higher after a strong quarterly report. Revenue inched slighting higher as MRI and CT scan volume increased modestly during the period. However, the real star in the report was RadNet's bottom line. Its cost-cutting and debt-slashing efforts paid off with net income soaring to $0.12 a share after clocking in at a $0.07 a share a year earlier. Analysts were only holding out for $0.05 a share. RadNet also helped improve its standing by boosting its guidance for all of 2014. You don't need any of RadNet's fancy imaging equipment to see that that's a healthy sign. Trex (TREX) -- Up 25 percent last week It was a good week for a pair of home improvement specialists. Shares of CaesarStone (CSTE) moved 20
No comments:
Post a Comment